

## **Sobi's Chairman of the Board resigns due to health reasons**

**Swedish Orphan Biovitrum AB's (publ) (Sobi®) (STO: SOBI) ("Sobi") Chairman of the Board Bo Jesper Hansen resigns, at his own request and with immediate effect, from his position as Chairman of the Board and board member due to health reasons.**

Bo Jesper Hansen has been deputy Chairman of the Board of Sobi since the annual general meeting in May 2022 and Chairman of the Board of Sobi since the annual general meeting in May 2023. Annette Clancy assumes with immediate effect the role of Chair of the Board. Annette has been a board member of Sobi since 2014 and has extensive experience from executive positions and board positions in the pharmaceutical industry.

"We regret that Bo Jesper needs to resign, and we thank him for his valuable contributions to Sobi", says Annette Clancy, Sobi's incoming Chair of the Board.

### **Sobi**

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at [sobi.com](https://sobi.com), [LinkedIn](#) and [YouTube](#).

### **Contacts**

For details on how to contact the Sobi Investor Relations Team, please click [here](#). For Sobi Media contacts, click [here](#).

This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 5 January 2024 at 8:00 CET.

Tobias Cottmann  
Investor Relations  
Phone +41 79 287 10 51